Blood Analyzers in North Carolina

Hemo bioscience is a North Carolina-based manufacturer of immunohematology reagents and blood banking diagnostics headquartered in Research Triangle Park. Founded over 20 years ago, the company specializes in transfusion diagnostics and serves blood banks, clinical laboratories, reference laboratories, buying groups, hospital blood banks, and donor centers. Their product portfolio includes blood typing reagents (including American Red Cross rare antisera), quality control materials for blood banking assays, red cell storage and treatment solutions (including DTT reagents), eluate kits for serological testing, validation and competency test kits, and proficiency testing materials. The ELU Clear Elution Kit (H360) is a flagship product available for direct purchase. The company manufactures high-quality reagents suitable for clinical laboratory and transfusion medicine applications. Their validation kits and educational materials support laboratory accreditation, competency assessment, and staff training. Products are distributed directly and through industry partners, with direct ordering available via phone and email.

Laboratory Corporation of America Holdings (Labcorp) is a global leader in laboratory services headquartered in Burlington, North Carolina. Operating in approximately 100 countries with over 70,000 employees, Labcorp performs more than 700 million tests annually and generates $13.01 billion in revenue. The company provides comprehensive clinical diagnostics, drug development support, and specialized testing including oncology, rare diseases, and genomic sequencing. Labcorp's integrated platform connects diagnostics to biopharma development, supporting healthcare providers, researchers, and investigators. Key offerings include AI-powered diagnostic assistance tools, real-world data platforms for drug development, genetic testing services (including Invitae), nonclinical research, central laboratory services, and clinical trial support. The company serves patients, healthcare providers, health systems, managed care organizations, and biopharmaceutical companies. Over 75% of new drugs approved by the FDA have been supported by Labcorp's services.

HemoSonics manufactures the Quantra® System, an FDA-cleared viscoelastic testing (VET) platform for real-time hemostasis assessment at the point of care. The Quantra System is the first and only viscoelastic testing platform FDA-cleared specifically for peripartum obstetric procedures, with additional FDA-cleared indications for cardiac surgery, trauma, liver transplantation, and major orthopedic surgery. The system delivers rapid, easy-to-interpret whole blood hemostasis data, enabling clinicians to make informed transfusion and hemostatic intervention decisions. Key product lines include QPlus® and QStat® Cartridges, which integrate with the Quantra analyzer. Clinical evidence demonstrates that viscoelastic testing reduces unnecessary blood product usage, length of hospital stay, transfusion-related complications, and time to hemostatic intervention. HemoSonics also offers External Quality Assessment (EQA) proficiency testing through partnership with sthemE Qualiris, providing comprehensive quality assurance for Quantra users. The company supports healthcare providers with implementation guidance, white papers on clinical and financial ROI, and educational resources. FDA 510(k) clearance and quality management system compliance underpin the product portfolio. The company targets hospital laboratories, operating rooms, and obstetric care teams seeking to optimize bleeding management protocols and reduce blood product consumption.

Precision Diabetes, Inc. is an emerging leader in precision medicine for diabetes, headquartered in Raleigh, North Carolina (Research Triangle Park). The company develops and markets novel diabetes biomarkers and diagnostic tests that span diabetes risk assessment through complication detection. Primary product is GlycoMark, a proprietary diabetes biomarker test for which Precision Diabetes holds exclusive distribution rights across the United States, Europe, Australia, Asia-Pacific, Middle East, and Mexico. GlycoMark is validated as a prediabetes biomarker and novel indicator of SGLT-2 inhibitor adherence; recent clinical data suggests utility in COVID-19 severity assessment. The company also partners with Patia Europe to distribute DIABETESpredict (type 2 diabetes genetic testing) and Matergen (gestational diabetes genetic testing) in the U.S. market. Precision Diabetes maintains a strategic partnership with DxGen Corp. to commercialize a point-of-care diabetes testing analyzer. The portfolio addresses both clinical laboratory and point-of-care testing modalities, serving endocrinology, primary care, and hospital laboratory markets. Company demonstrates active clinical research engagement, with publications and presentations at major conferences including the American Diabetes Association.

CellaVision AB is a global leader in digital hematology microscopy solutions with over 30 years of experience. Headquartered in Lund, Sweden, the company operates in 13 regional markets with presence in over 40 countries and has sold more than 9,500 units worldwide. CellaVision provides integrated digital cell morphology systems including analyzers, instruments, reagents, software, and training solutions for hematology laboratories. The product suite covers analysis of human and animal blood and body fluid samples, including bone marrow aspirate applications. CellaVision Software 7.2 represents their latest digital cell morphology platform, designed to automate laboratory workflows, minimize human error, and enhance cross-site collaboration. Manufacturing of analyzers is outsourced in Sweden while stain reagents are manufactured in-house in Bordeaux, France. The company employs 250 staff globally and serves reference, hospital, and diagnostic laboratories. Products support routine hematology analysis, proficiency testing, training, and education. Regulatory compliance and quality standards are integral to their offerings, as evidenced by customer adoption across major healthcare networks in Canada, India, Sweden, and the United States.

Thermo Fisher Scientific is a global leader in life sciences and laboratory equipment, consumables, and digital solutions. The company manufactures and distributes a comprehensive portfolio of products for research, diagnostics, and bioprocessing applications across academic, pharmaceutical, biotechnology, and clinical laboratory markets. Product lines include transmission electron microscopes (Glacios 3 Cryo-TEM for structural biology), cell culture media and supplements (Gibco brand), molecular biology reagents (TaqMan and SuperScript PCR systems), transfection reagents (Lipofectamine), assay kits, fetal bovine serum, laboratory consumables (tubes, plates, magnetic beads), and analytical instruments. The company serves drug discovery, genomics, proteomics, cell culture, viral production, and materials analysis workflows. Thermo Fisher operates a robust e-commerce platform with online ordering of thousands of SKUs, technical support resources, interactive media selection tools, and educational content. The organization maintains ISO certifications and FDA compliance for its clinical and diagnostic products, with manufacturing facilities and distribution networks across North America and globally.